The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas
type: Distribution
access URL: https://ens-lyon.hal.science/ensl-00817062
format: HTML
issued: 2026-05-11T08:35:17.944340
modified: 2026-05-11T08:35:17.918025

The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas
type: Dataset
contact point: Organization
  fn: CCSD
keyword: multiple-myeloma
keyword: b-cell-lymphoproliferative-disorder
keyword: hgf
keyword: sdvcanlife-sciences-q-biocancer
keyword: met
keyword: diffuse-large-b-cell-lymphoma
keyword: journal-articles
keyword: infoeu-reposemanticsarticle
landing page: 0304-419X
description: Hepatocyte growth factor (HGF) and its receptor MET are essential during embryonic development and throughout postnatal life. However, aberrant MET activation, due to overexpression, mutations, or autocrine ligand production, contributes to the development and progression of a variety of human cancers, often being associated with poor clinical outcome and drug resistance. B cell malignancies arise from B cells that are clonally expanded at different stages of differentiation. Despite major therapeutic advances, most mature B cell malignancies remain incurable and biologically-oriented therapeutic strategies are urgently needed. This review addresses the role of the HGF/MET pathway during B cell development and discusses how its aberrant activation contributes to the development of B cell lymphoproliferative disorders, with particular emphasis on multiple myeloma and diffuse large B cell lymphoma. These insights, combined with the recent development of clinical-grade agents targeting the MET pathway, provide the rationale to envision the HGF/MET pathway as a new promising target for the treatment of B cell malignancies.
issued: 2026-05-11T08:35:17.929247
language: en
modified: 2026-05-11T08:35:17.929252

test_moissonnage_selune
type: Agent